TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02146924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01695941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT
Study: NCT03416712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening survey and accompanying handout for resources
Description: Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
Study: NCT02672722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Ultrasound
Description: This done before and after exercise with the help of Definity to see changes in kidney blood flow
Study: NCT02825485

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Voiding cystourethrogram
Study: NCT04287478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage Therapy
Description: Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
Study: NCT00936507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Density/Portion Size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Density/Portion Size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Density/Portion Size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Density/Portion Size
Study: NCT03819816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEA-App
Description: The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Information group
Description: The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
Study: NCT01063140

Intervention type: BIOLOGICAL
Intervention: Rabies Vaccine (RabAvert)
Description: The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.

Intervention type: BIOLOGICAL
Intervention: Rabies Vaccine (Imovax)
Description: The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
Study: NCT01954407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking-Related Messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking-Related Messages
Study: NCT04287894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Per day 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Per day 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Per day 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 on day 1 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 on day 1 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 on day 1 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 mg / m2 on day 1 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 mg / m2 on day 1 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 6 mg / m2 on day 1 every 3 weeks for 2 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemo radiotherapy
Description: Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemo radiotherapy
Description: Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
Study: NCT03508635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Challenge agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Challenge agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Study: NCT01881841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cMET
Description: Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
Study: NCT05062941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity laser therapy (HILT)
Description: HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total.
Study: NCT02326207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infant Ventilator Circuit Dual Heated with Autofeed Chamber

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infant Ventilator Circuit Dual Heated with Autofeed Chamber
Study: NCT02499341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
Study: NCT01848899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: contrast media used during coronary angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Description: contrast media used during coronary angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: A direct thrombin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: A direct thrombin inhibitor
Study: NCT00379197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
Study: NCT05412472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 45 mg IV infusion of GC4419 over 60 minutes.
Study: NCT04287894

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemo radiotherapy
Description: Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: After CIT-CRT
Study: NCT05412472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 45 mg IV infusion of GC4419 over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 45 mg IV infusion of GC4419 over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 45 mg IV infusion of GC4419 over 60 minutes.
Study: NCT03925961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education
Description: The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education
Description: The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
Study: NCT02199106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left temporal verum cTBS
Description: Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left temporal placebo cTBS
Description: Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS
Study: NCT01140854

Intervention type: PROCEDURE
Intervention: Lumbar spine surgery
Description: (non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
Study: NCT00805155

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

Intervention type: DRUG
Intervention: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study: NCT02448849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Percutaneous injection
Description: percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous injection
Description: Percutaneous implantation of placebo in patients with nonunion fracture.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT
Study: NCT01476228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG recording
Description: EEG recording
Study: NCT02823314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cure Tape™ covering T 7 and T 8 dermatomes
Description: The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cure Tape™ away from dermatomes T 7 and T 8
Description: The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
Study: NCT02207335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine，Capecitabine
Description: Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Carboplatin
Description: Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
Study: NCT04287894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: After CIT-CRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: After CIT-CRT
Study: NCT00390299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic Antigen-Expressing Measles Virus
Description: Given via injection into resection cavity or around tumor bed and/or IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic Antigen-Expressing Measles Virus
Description: Given via injection into resection cavity or around tumor bed and/or IT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo en bloc resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo en bloc resection
Study: NCT00235508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone (Lunesta)
Description: Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone (Lunesta)
Description: Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
Study: NCT02751138

Intervention type: PROCEDURE
Intervention: Surgery
Description: Tumor resection

Intervention type: PROCEDURE
Intervention: Surgery
Description: Tumor resection
Study: NCT01666704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2mg, Once daily, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 15mg, Once daily, 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0mg, Once daily, 1 year
Study: NCT01750866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
Study: NCT02665988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
Study: NCT03751943

Intervention type: DEVICE
Group type: OTHER
Intervention: NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)
Description: NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
Study: NCT01359436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensing)
Description: Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
Study: NCT00433199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone (T) Gel 1.62%
Description: Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control